Abstract:Background: COVID-19 is an ongoing global pandemic. Changes in haematological characteristics in patients with COVID-19 are emerging as important features of the disease. We aimed to explore the haematological characteristics and related risk factors in patients with COVID-19. Methods: This retrospective cohort study included patients with COVID-19 admitted to three designated sites of Wuhan Union Hospital (Wuhan, China). Demographic, clinical, laboratory, treatment, and outcome data were extracted from electronic medical records and compared between patients with moderate, severe, and critical disease (defined according to the diagnosis and treatment protocol for novel coronavirus pneumonia, trial version 7, published by the National Health Commission of China). We assessed the risk factors associated with critical illness and poor prognosis. Dynamic haematological and coagulation parameters were investigated with a linear mixed model, and coagulopathy screening with sepsis-induced coagulopathy and International Society of Thrombosis and Hemostasis overt disseminated intravascular coagulation scoring systems was applied. Findings: Of 466 patients admitted to hospital from Jan 23 to Feb 23, 2020, 380 patients with COVID-19 were included in our study. The incidence of thrombocytopenia (platelet count <100 x 109 cells per L) in patients with critical disease (42 [49%] of 86) was significantly higher than in those with severe (20 [14%] of 145) or moderate (nine [6%] of 149) disease (p<0.0001). The numbers of lymphocytes and eosinophils were significantly lower in patients with critical disease than those with severe or moderate disease (p<0.0001), and prothrombin time, D-dimer, and fibrin degradation products significantly increased with increasing disease severity (p<0.0001). In multivariate analyses, death was associated with increased neutrophil to lymphocyte ratio (>= 9.13; odds ratio [OR] 5.39 [95% CI 1.70-17.13], p=0.0042), thrombocytopenia (platelet count <100 x 109 per L; OR 8.33 [2.56-27.15], p=0.00045), prolonged prothrombin time (>16 s; OR 4.94 [1.50-16.25], p=0.0094), and increased D-dimer (>2 mg/L; OR 4.41 [1.06-18.30], p=0.041). Thrombotic and haemorrhagic events were common complications in patients who died (19 [35%] of 55). Sepsis-induced coagulopathy and International Society of Thrombosis and Hemostasis overt disseminated intravascular coagulation scores (assessed in 12 patients who survived and eight patients who died) increased over time in patients who died. The onset of sepsis-induced coagulopathy was typically before overt disseminated intravascular coagulation. Interpretation: Rapid blood tests, including platelet count, prothrombin time, D-dimer, and neutrophil to lymphocyte ratio can help clinicians to assess severity and prognosis of patients with COVID-19. The sepsis-induced coagulopathy scoring system can be used for early assessment and management of patients with critical disease. Copyright (C) 2020 Elsevier lid. All rights reserved.

Hematological characteristics of COVID‐19 patients with fever infected by the Omicron variant in Shanghai: A retrospective cohort study in China

Characteristics of hematological parameters on admission in COVID-19 Omicron variant infected in Chinese population: a large-scale retrospective study

Analysis of Blood Index Characteristics in COVID-19 Patients and Their Associations with Different Outcomes

Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China

Clinical manifestations of blood cell parameters and inflammatory factors in 92 patients with COVID-19

Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019

Epidemiological characteristics of patients from fever clinics during the COVID-19 epidemic in 2022 in Shanghai, China

Haematological Characteristics and Risk Factors in the Classification and Prognosis Evaluation of COVID-19: a Retrospective Cohort Study.

Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China

Analysis of Peripheral Blood IL-6 and Leukocyte Characteristics in 364 COVID-19 Patients of Wuhan

Epidemiological characteristics of patients from fever clinics with COVID-19 epidemic in 2022 in Shanghai, China.

Clinical Features and Blood Indicators for Severity and Prognosis in COVID-19 Patients.

Chronological Changes of Viral Shedding in Adult Inpatients with Omicron Infection in Shanghai, China

Hematologic changes predict clinical outcome in recovered patients with COVID-19

Hematological findings in coronavirus disease 2019: indications of progression of disease

Systematic Evaluation of Hematologic Parameters and Blood Smear Findings in Patients With SARS-CoV-2 vs Other Viral Respiratory Infections

Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study

"Lymphocyte * Neutrophil" count decreased in SARS-CoV-2 Omicron patients in Shanghai with no significant change in CRP and SAA

Clinical characteristics of 1139 mild cases of the SARS‐CoV‐2 Omicron variant infected patients in Shanghai

Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era

Clinical Progression and Outcome of Hospitalized Patients Infected with SARS-CoV-2 Omicron Variant in Shanghai, China